EPISODE · Mar 26, 2021 · 11 MIN
Ivacaftor: Long term adherence and outcomes
from Thorax Podcast · host BMJ Group
The recent development of triple CFTR modulation means that up to 90% of people with CF will be eligible for ‘highly effective’ CFTR modulator therapy. In this podcast, Rachael Moses, Multimedia Editor of Thorax, and Dr Peter Barry, Consultant Respiratory Physician, Manchester Adult Cystic Fibrosis Centre, discuss the long-term adherence to and effects of ivacaftor on lung function, weight and healthcare utilisation in people with cystic fibrosis and the Gly551Asp mutation. Read the related paper: https://thorax.bmj.com/content/early/2021/03/24/thoraxjnl-2020-215556
What this episode covers
The recent development of triple CFTR modulation means that up to 90% of people with CF will be eligible for ‘highly effective’ CFTR modulator therapy. In this podcast, Rachael Moses, Multimedia Editor of Thorax, and Dr Peter Barry, Consultant Respiratory Physician, Manchester Adult Cystic Fibrosis Centre, discuss the long-term adherence to and effects of ivacaftor on lung function, weight and healthcare utilisation in people with cystic fibrosis and the Gly551Asp mutation. Read the related paper: https://thorax.bmj.com/content/early/2021/03/24/thoraxjnl-2020-215556
NOW PLAYING
Ivacaftor: Long term adherence and outcomes
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m